Our Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing (cytotoxic) agent specifically to cancer cells. Each TAP compound consists of an antibody that binds to a target found on cancer cells with an ImmunoGen-proprietary cell-killing agent attached. The antibody enables the compound to specifically target cancer cells and the cytotoxic agent serves to kill these cells.